Marguerite is a PhD student specializing in cancer immunotherapies. Her research aims to explore innovative strategies for the translational development of T cell therapies, with a focus on enhancing T cell metabolism and overcoming resistance posed by immunosuppressive tumour microenvironments. She conducts genome-wide CRISPR screens to identify key target genes that limit adoptive T cell fitness, persistence, and efficacy. Through her expertise in gene editing and T cell engineering, she seeks to advance cellular therapies for broader application in patients, particularly those with solid tumors.
Marguerite holds a PharmD from Université de Caen Normandie and a Master’s in Biotechnology from Université de Grenoble and Grenoble Ecole de Management.
Recent publications
- Trends in Cancer · 2026Epigenetic, epitranscriptomic, and metabolic control of T cell exhaustion
- Nature Biomedical Engineering · 2024Ablation of FAS confers allogeneic CD3– CAR T cells with resistance to rejection by T cells and natural killer cells
- STAR Protocols · 2023Optimized protocol to generate genome-wide inactivated Cas9-expressing murine T cells